China Biologic Products Holdings, Inc. (CBPO) Given $111.67 Consensus Target Price by Brokerages

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Brokers have set a twelve-month consensus price target of $111.67 for the company and are expecting that the company will post $1.11 earnings per share for the current quarter, according to Zacks. Zacks has also assigned China Biologic Products an industry rank of 107 out of 265 based on the ratings given to its competitors.

CBPO has been the topic of several recent analyst reports. BidaskClub upgraded China Biologic Products from a “strong sell” rating to a “sell” rating in a report on Wednesday. Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th.

China Biologic Products (CBPO) traded down $0.62 during trading on Friday, hitting $79.81. The stock had a trading volume of 94,000 shares, compared to its average volume of 237,407. The firm has a market cap of $2,220.62, a price-to-earnings ratio of 17.91, a P/E/G ratio of 1.31 and a beta of 1.78. China Biologic Products has a 52 week low of $72.21 and a 52 week high of $120.46.

Several large investors have recently added to or reduced their stakes in CBPO. Hillhouse Capital Management Ltd. lifted its holdings in shares of China Biologic Products by 186.8% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 753,624 shares of the biopharmaceutical company’s stock valued at $85,235,000 after purchasing an additional 490,874 shares in the last quarter. Schroder Investment Management Group lifted its stake in China Biologic Products by 771.5% in the 2nd quarter. Schroder Investment Management Group now owns 544,676 shares of the biopharmaceutical company’s stock valued at $60,845,000 after acquiring an additional 482,175 shares in the last quarter. Macquarie Group Ltd. lifted its stake in China Biologic Products by 115.3% in the 2nd quarter. Macquarie Group Ltd. now owns 587,587 shares of the biopharmaceutical company’s stock valued at $66,456,000 after acquiring an additional 314,700 shares in the last quarter. Artisan Partners Limited Partnership lifted its stake in China Biologic Products by 62.9% in the 3rd quarter. Artisan Partners Limited Partnership now owns 723,859 shares of the biopharmaceutical company’s stock valued at $66,790,000 after acquiring an additional 279,420 shares in the last quarter. Finally, Comgest Global Investors S.A.S. lifted its stake in China Biologic Products by 135.0% in the 3rd quarter. Comgest Global Investors S.A.S. now owns 356,252 shares of the biopharmaceutical company’s stock valued at $32,872,000 after acquiring an additional 204,649 shares in the last quarter. Institutional investors and hedge funds own 65.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2017/12/22/china-biologic-products-holdings-inc-cbpo-given-111-67-consensus-target-price-by-brokerages.html.

China Biologic Products Company Profile

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit